依达拉奉注射液治疗急性脑梗死的临床疗效评价

Clinical Efficacy of Edaravone on the Patients with Acute Cerebral Infaraction

目的观察加用依达拉奉注射液(必存注射液)治疗急性脑梗死的临床疗效。方法98例急性脑梗死患者随机分为治疗组和对照组,每组49例,治疗组给予依达拉奉注射液30mg静脉滴注,2次/d,同时给予奥扎格雷、胞二磷胆碱作为基础治疗;对照组用常规治疗方法。比较两组的总显效率、脑水肿程度、治疗7d、14d神经功能缺损评分进行疗效评定。结果治疗组总显效率为91.8%,对照组为81.6%,两组无显著差异;治疗组脑水肿轻度为81.6%,对照组为65.4%,2组间有显著差异;7d、14d神经功能缺损评分治疗组与对照组相比有显著差异。结论依达拉奉注射液治疗急性脑梗死安全有效,能有效改善急性脑梗死的神经功能缺失,未见明显不良反应。

Objective To evaluate the clinical efficacy of Edaravone on acute cerebral infarction（ACI）. Methods Ninty-eight patients who suffered ACI were ran（h）mly divided into therapy group（ n = 49） and control group（ n = 49）. Edaravone was infused at a dose of 30mg, twice a （lay, meanwhile, Ozagrel and Citicoline were take as hasie treatment. The control group was similar to those of therapy group except for Edaravone. Compare with the total efficiency, brain edema scale and necurologieal functional deficit scores on the 7th, 14th day after treatment. Results There was no significant difference between tile two group interns of total apparent effect rate （therapy group：91.8 % ;control group：81.6 % ）. A significant correlation was found between the therapy group and the control group of Brain edema （therapy group：81.6% ;control group：65.4% ） . The ratio of neeurological functional deficit senres on the 7th, 14th day after treatment in therapy group were significantly higher than that in control group. Conclusion Edaravone is a new effectivc and safe neumprotective agent for treating aeute cerebral infarction, it can aeeelerate the reeovery of neural function after cerebral infarction.There was no distinct adverse reaction in Edaravone group.